Menu Search
Equities

Jazz Pharmaceuticals PLC

JAZZ:NSQ

Jazz Pharmaceuticals PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)125.34
  • Today's Change0.24 / 0.19%
  • Shares traded140.56k
  • 1 Year change+2.97%
  • Beta0.5699
Data delayed at least 15 minutes, as of Nov 22 2024 15:32 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy5
Outperform10
Hold4
Sell0
Strong Sell0

Share price forecast in USD

The 18 analysts offering 12 month price targets for Jazz Pharmaceuticals PLC have a median target of 180.50, with a high estimate of 230.00 and a low estimate of 128.00. The median estimate represents a 44.28% increase from the last price of 125.10.
High83.9%230.00
Med44.3%180.50
Low2.3%128.00

Earnings history & estimates in USD

On Nov 06, 2024, Jazz Pharmaceuticals PLC reported 3rd quarter 2024 earnings of 6.61 per share. This result exceeded the 5.50 consensus of the 17 analysts covering the company and exceeded last year's 3rd quarter results by 36.57%.
The next earnings announcement is expected on Feb 25, 2025.
Average growth rate+19.90%
Jazz Pharmaceuticals PLC reported annual 2023 earnings of 18.29 per share on Feb 28, 2024.
Average growth rate+6.73%
More ▼

Revenue history & estimates in USD

Jazz Pharmaceuticals plc had 3rd quarter 2024 revenues of 1.05bn. This bettered the 1.04bn consensus of the 18 analysts covering the company. This was 18.16% above the prior year's 3rd quarter results.
Average growth rate+2.44%
Jazz Pharmaceuticals plc had revenues for the full year 2023 of 3.83bn. This was 4.78% above the prior year's results.
Average growth rate+15.82%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.